Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition

Stem Cells

Volumn 27, Issue 2, 2009, Pages 467-477

  Copland, Ian B ^a   Lord Dufour, Simon ^b   Cuerquis, Jessica ^a   Coutu, Daniel L ^a   Annabi, Borhane ^b   Wang, Eugenea ^c   Galipeau, Jacques ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c University of Louisville School of Medicine   (United States)

Author keywords

Bone marrow stromal cells; Cell transplantation; Hypoxia; Ischemia; Plasminogen activator inhibitor 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOIKIS; ARTICLE; AUTOGRAFT; CELL ADHESION; CELL SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; HUMAN; HUMAN CELL; ISCHEMIA; MESENCHYME CELL; MOUSE; NONHUMAN; NORMAL HUMAN; PROTEOMICS; STROMA CELL;

ANIMALS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; FEMALE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, INBRED C57BL; MYOCARDIAL ISCHEMIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 62549161345     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0520     Document Type: Article

References (53)

1. Caplice NM, Gersh BJ, Alegria JR. Cell therapy for cardiovascular disease: What cells, what diseases and for whom? Nat Clin Pract Car-diovasc Med 2005;2:37-43.
2. Wang Y, Haider HK, Ahmad N et al. Combining pharmacological mobilization with intramyocardial delivery of bone marrow cells over-expressing VEGF is more effective for cardiac repair. J Mol Cell Cardiol 2006;40:736-745.
3. Mangi AA, Noiseux N, Kong D et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-1201.
4. Shake JG, Gruber PJ, Baumgartner WA et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: Engraftment and functional effects. Ann Thorac Surg 2002:73:1919-1925, discussion 1926.
5. Chen SL, Fang WW, Ye F et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004;94:92-95.
6. Stagg J, Galipeau J. Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol 2007:45-66.
7. Mooney DJ, Vandenburgh H. Cell delivery mechanisms for tissue repair. Cell Stem Cell 2008;2:205-213.
8. Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell 2008; 132:544-548.
9. Muller-Ehmsen J, Krausgrill B, Burst V et al. Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction. J Mol Cell Cardiol 2006;41:876-884.
10. Li JH Zhang N, Wang JA. Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. J Endocrinol Invest 2008:31:103-110.
11. Wang JA, Chen TL, Jiang J et al. Hypoxic preconditioning attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells. Acta Pharmacol Sin 2008;29:74-82.
12. Hung SC. Pochampally RR, Hsu SC et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS ONE 2007; 2:e416.
13. Poiter E. Ferreira E. Meunier A et al. Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death. Tissue Eng 2007;13:1325-1331
14. Caplan AI, Dennis .JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006;98:1076-1084.
15. Eliopoulos N, Al-Khaldi A, Crosato M et al. A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloabiated, immunocompetent mice. Gene Ther 2003;10:478 - 489.
16. Pittcngcr MF, Mackay AM, Beck SC. et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999:284:143-147.
17. Phinney DG. Isolation of mesenchymal stem cells from murine bone marrow by immunodepletion. Methods Mol Biol 2008:449: 171-186.
18. Copland I, Sharma K, Lejeune L et al. CD34 expression on murine marrow-derived mesenchymal stromal cells: Impact on neovascularization. Exp Hematol 2008:36:93-103.
19. Tusher VG. Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121.
20. Cong YS, Fan E, Wang E. Simultaneous proteomic profiling of four different growth states of human fibroblasts, using amine-reactive iso-baric tagging reagents and tandem mass spectrometry. Mech Ageing Dev 2006;127:332-343.
21. Hockin MF, Kalafatis M, Shatos M et al. Protein C activation and factor Va in activation on human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 1997;17:2765-2775.
22. Annabi B, Lachambre M, Bousquet-Gagnon N et al. Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochem J 2001;353:547-553.
23. Al-Khaldi A, Eliopoulos N, Martineau D et al. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther 2003;10:621-629.
24. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retro virus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A 1996;93:11400-11406.
25. Mylotte LA, Duffy AM, Murphy M et al. Metabolic flexibility permits mesenchymal stem cell survival in an ischemic environment. STEM CELLS 2008;26:1325-1336.
26. Beissbarth T, Speed TP. GOstat: Find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 2004:20:1464-1465.
27. Cesarman-Maus G. Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005;129:307-321.
28. Monea S, Lehti K, Keski-Oja J et al. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 2002;192:160-170.
29. Davis GE, Pintar Allen KA, Salazar R et al. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci 2001; 114:917-930.
30. Al-Fakbri N. Chavakis T. Schmidt-Woll T et al. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininosen correlates with their anti-adhesive properties. Biol Chem 2003;384:423-435.
31. Czekay RP, Aertgeerts K, Curriden SA et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003;160:781-791.
32. Balsara RD, Xu Z, Ploplis VA. Targeting plasminogen activator inhibitor- 1: Role in cell signaling and the biology of domain-specific knock-in mice. Curr Drug Targets 2007;8:982-995.
33. Park HW, Shin JS, Kim CW. Proteome of mesenchymal stem cells. Proteomies 2007;7:2881-2894.
34. Schinkothe T, Bloch W, Schmidt A. In vitro secreting profile of human mesenchymal stem cells. Stem Cells Dev 2008;17:199-206.
35. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: Links, causes, and consequences. Arterioscler Thromb Vase Biol 2006:26: 2200-2207.
36. Chan JC, Duszczyszyn DA, Castellino FJ et al. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 2001;159:1681-1688.
37. Carmeliet P, Moons L, Lijnen R et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice. Circulation 1997;96: 3180-3191.
38. Koh TJ, Bryer SC, Pucci AM et al. Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration. Am J Physiol Cell Physiol 2005;289:C217-223.
39. Alfano D, Franco P. Vocca 1 et al. The urokinase plasminogen activator and its receptor: Role in cell growth and apoptosis, Thromb Haemost 2005;93:205-211.
40. Chiellini C, Cochet O, Negroni L et al. Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Mol Biol 2008;9:26.
41. Meilhac O Ho-Tin-Noe B, Tlouard X et al. Pericellular plasmin induces smooth muscle cell anoikis. FASEB J 2003;17:1301-1303.
42. Michel JB. Anoikis in the cardiovascular system: Known and unknown extracellular mediators. Arterioscler Thromb Vase Biol 2003; 23:2146-2154.
43. Myohanen H, Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 2004;61:2840-2858.
44. Davis ME. Motion JP, Narmoneva DA et al. Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 2005;111:442-450.
45. Hill E, Boontheekul T, Mooney DJ. Regulating activation of transplanted cells controls tissue regeneration. Proc Natl Acad Sci U S A 2006; 103: 2494-2499.
46. Delaney C, Varnurn-Finney B, Aoyama K et al Dose-dependent effects of the Notch ligand Deltal on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood 2005;106:2693-2699.
47. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-626.
48. Meredith JE Jr. Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-961.
49. Fibbi G, D'Alessio S, Pucci M et al. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system. Biol Chem 2002;383:127-136.
50. Quax PR Frisdal E, Pedersen N et al. Modulation of activities and RNA level of the components of the plasminogen activation system during fusion of human myogenic satellite cells in vitro. Dev Biol 1992; 151: 166-175.
51. Smadja DM, Basire A, Amelot A et al. Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells. J Cell Mol Med 2008;12:975-986.
52. Tessmar JK, Gopferich AM. Matrices and scaffolds for protein delivery in tissue engineering. Adv Drug Deliv Rev 2007;59:274-291.
53. Hey mans S, Luttun A, Nuyens D et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999;5:1135-1142.